Identification of 27 allele-specific regulatory variants in Parkinson’s disease using a massively parallel reporter assay

被引:0
作者
Sophie L. Farrow
Sreemol Gokuladhas
William Schierding
Michael Pudjihartono
Jo K. Perry
Antony A. Cooper
Justin M. O’Sullivan
机构
[1] The University of Auckland,Liggins Institute
[2] The University of Auckland,The Maurice Wilkins Centre
[3] The University of Auckland,Department of Ophthalmology
[4] Garvan Institute of Medical Research,Australian Parkinsons Mission
[5] University of New South Wales,St Vincent’s Clinical School
[6] Agency for Science Technology and Research,Singapore Institute for Clinical Sciences
[7] University of Southampton,MRC Lifecourse Epidemiology Unit
来源
npj Parkinson's Disease | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Genome wide association studies (GWAS) have identified a number of genomic loci that are associated with Parkinson’s disease (PD) risk. However, the majority of these variants lie in non-coding regions, and thus the mechanisms by which they influence disease development, and/or potential subtypes, remain largely elusive. To address this, we used a massively parallel reporter assay (MPRA) to screen the regulatory function of 5254 variants that have a known or putative connection to PD. We identified 138 loci with enhancer activity, of which 27 exhibited allele-specific regulatory activity in HEK293 cells. The identified regulatory variant(s) typically did not match the original tag variant within the PD associated locus, supporting the need for deeper exploration of these loci. The existence of allele specific transcriptional impacts within HEK293 cells, confirms that at least a subset of the PD associated regions mark functional gene regulatory elements. Future functional studies that confirm the putative targets of the empirically verified regulatory variants will be crucial for gaining a greater understanding of how gene regulatory network(s) modulate PD risk.
引用
收藏
相关论文
共 115 条
[31]  
Avramopoulos DG(2022)Establishing gene regulatory networks from Parkinson’s disease risk loci Brain 139 693142-833
[32]  
Goff LA(2021)Unravelling the Shared Genetic Mechanisms Underlying 18 Autoimmune Diseases Using a Systems Approach Front. Immunol. 12 103046-640
[33]  
Hansen KD(2023)Juvenile idiopathic arthritis-associated genetic loci exhibit spatially constrained gene regulatory effects across multiple tissues and immune cell types J. Autoimmun. 138 944-388
[34]  
Abell NS(2014)A framework for the interpretation of de novo mutation in human disease Nat. Genet. 46 434-142
[35]  
Burgess DJ(2020)The mutational constraint spectrum quantified from variation in 141,456 humans Nature 581 1-2067
[36]  
Steinhaus R(2022)Genetic variation as a long-distance modulator of RAD21 expression in humans Sci. Rep. 12 1-346
[37]  
Robinson PN(2020)Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells npj Park. Dis. 6 822-248
[38]  
Seelow D(2008)Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease Am. J. Hum. Genet. 82 637-9
[39]  
Ward LD(2015)GIGYF2 mutation in late-onset Parkinson’s disease with cognitive impairment J. Hum. Genet. 60 377-S100
[40]  
Kellis M(2023)Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases Nat. Genet. 55 135-74